I sat through another boardroom presentation last week. The CEO was glowing. Slides showed revenue curves pointing northeast, a roadmap to parity with industry leaders, and a narrative about 'technology sovereignty' that had every VC in the room nodding. I was the only one staring at the footnote: 'Capex coverage ratio is 1.2x OC FCF. Excluding government grants, it is 0.3x.' That footnote was the truth. The slides were the marketing. The founder was pitching a dream; I was auditing a dependency.
ChangXin Memory Technologies (CXMT) just filed its STAR Market IPO prospectus. Chairman Zhu Yiming called it a 'new beginning.' It is. But not the kind the prospectus wants you to believe. This is not a story about China catching up in DRAM. This is a story about a company that has mastered one thing—building chips with restricted tools—but has not yet proven it can build a business. The code was solid; the logic was not.
Context: The Hype Cycle Trap
DRAM is a $80 billion market. Samsung, SK Hynix, and Micron control 96% of it. CXMT holds less than 3%. The thesis is simple: China needs domestic DRAM, CXMT is the only game in town, and if it captures even 20% of the Chinese market, it becomes a $10 billion revenue company. The STAR Market loves this narrative. It sells. But narratives are not financial statements.
CXMT has one fab in Hefei, running at approximately 80-85% utilization. Its leading node is 17nm (1-alpha), using DUV lithography with multiple patterning. Samsung and SK Hynix are already in 1-beta with EUV. The technology gap is two to three years. That gap is not closing linearly; it is compressing only because CXMT skipped intermediate nodes. But every node shrink from here on requires either EUV—which is blocked—or a much higher degree of process complexity that drives down yield and up cost. CXMT's yield on 17nm is estimated at 70-80%. At 15nm, it may drop to 50-60%. The math does not favor the story.
Core: The Systematic Teardown
Let me walk through the three variables that will determine whether CXMT is a return on capital or a black hole.
Variable 1: HBM is a mirage.
The biggest hype driver in CXMT's story is HBM. AI servers need high-bandwidth memory. CXMT has HBM2E in small production and claims HBM3 by 2025. But HBM is not just a design problem; it is a packaging and supply chain problem. The TSV (through-silicon via) and micro-bumping processes required for HBM are entirely dependent on advanced packaging equipment—much of which is also under export controls. CXMT is building its own TSV line from scratch. That is a three-year, billion-dollar experiment with no guarantee of yield. Meanwhile, SK Hynix is already shipping HBM3E with 8-Hi stacks at 85% yield. The gap is not two years; it is an entire generation. Volatility hides in the compounding fractions.
Variable 2: Equipment dependency is the real balance sheet.
CXMT's capex is over 80% of revenue. That is unsustainable by any conventional standard. The company is buying every available DUV tool on the secondary market, hoarding spare parts, and paying premiums for used ASML NXT:1980Ci units. But here is the risk that no prospectus quantifies: if the U.S. or Netherlands extends export controls to cover all 0.33NA DUV tools—including refurbished units—CXMT's expansion plan collapses. The third-phase Hefei expansion targets 200K wafers per month by 2026. Over 60% of the required equipment is already delivered. But the remaining 40% represents the critical, high-precision tools that cannot be substituted with domestic alternatives. Minting fails when the math breaks trust.
The company's cash flow statement tells the real story. Operating cash flow turned positive in 2023, but only because of two factors: a cyclical DRAM price recovery and government subsidies disguised as 'other operating income.' Excluding such items, CXMT's operating cash flow is barely positive. Free cash flow remains deeply negative—by over 50 billion RMB annually. The IPO is not for expansion; it is to refinance debt and pre-pay equipment deposits to lock in supply before the next restriction wave.
Variable 3: The 'S' in STAR Market stands for 'Speculation.'
CXMT is seeking a valuation of 500-800 billion RMB pre-IPO. That implies a price-to-sales ratio of 8-10x on current revenue of ~60 billion RMB. For context, Micron trades at 3.5x sales. SK Hynix at 4x. CXMT's premium is entirely a function of 'national champion' status and A-share liquidity. The problem is that if CXMT misses even one earnings cycle due to a DRAM price correction—which is statistically likely given the industry's four-year cycle—the multiple compression will be violent. A flat line is more dangerous than a spike.
Contrarian Angle: What the Bulls Got Right
I am not here to burn straw men. The bulls have two strong arguments that deserve respect.
First, CXMT does not need to beat Samsung. It only needs to survive. The Chinese government has committed over 300 billion RMB in subsidies through the third-phase Big Fund. CXMT is the only DRAM manufacturer with viable 17nm production in China. The state will not let it fail. This is not a thesis about earnings; it is a thesis about existential backing. And in a world where capital is scarce for Chinese tech, that backing is a real moat.
Second, the domestic replacement narrative is real. Chinese server OEMs, government procurement, and telecom operators are under explicit instructions to prioritize domestic memory. CXMT has already locked in non-cancellable supply agreements with major customers like Huawei and Inspur. Even if CXMT's product is 10-15% more expensive, the buyer has no choice. That pricing power is a structural advantage that no Western competitor can replicate.
But here is the catch: the contrarian view only works if CXMT delivers on its timeline. If HBM3 misses 2025, if the third-phase fab ramps six months late, if the 15nm yield stays below 60%—the entire thesis shifts from 'growth' to 'zombie.' And zombie companies propped up by state funds do not make good public market investments.
Takeaway: The Only Signal That Matters
The prospectus is 500 pages. But there is only one paragraph to watch: the risk factors related to equipment supply. If the IPO document uses the phrase 'may be delayed due to regulatory approvals' more than three times, you have your answer. CXMT is not a technology company; it is a geopolitical instrument that happens to manufacture chips. The market will eventually figure that out, but only after the lock-up period expires.
Check the inputs, ignore the hype. The inputs here are equipment delivery timelines, yield data, and cash burn rates. Everything else is narrative. And narratives do not clear your margin call.
